Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DROSPIRENONE & ETHINYL ESTRADIOL

All products: general benefit

Other products in the same Health Canada class (G03A, G03AA) — coverage varies; not interchangeable

  • Desogestrel + ethinyl estradiol (Marvelon 21): general benefit
  • Ethinyl estradiol + levonorgestrel (Alesse 21): general benefit, Not a benefit
  • Ethinyl estradiol + norethindrone (Brevicon): general benefit
  • Ethinyl estradiol + norethindrone (Minestrin 1/20): general benefit
  • Drospirenone (Slynd): general benefit
  • Levonorgestrel (Plan B): general benefit

3 more in the class list below

Yaz · DIN 02321157 · 3.0mg & 0.02mg · tablets, 28-pack

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Yaz · DIN 02321157 Manufacturer: Bayer Inc., Health Care Division; listing date 2009-09-30 Health Canada: Marketed since 2009-01-06 · brand YAZ · ATC G03AA12 DROSPIRENONE AND ESTROGEN · form Tablet · route Oral · ingredients DROSPIRENONE 3 MG, ETHINYL ESTRADIOL 0.02 MG · company Bayer inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $8.2600 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80656 · Verify on the e-Formulary ↗ (DIN 02321157)

Source record
DIN 02321157: Yaz Raw flags: sec3=Y Item: 683200111; group id 796; item number 1937; lccId None; manufacturer id BAH Source form: Tab-28 Pk; strength: 3.0mg & 0.02mg Recorded listing: General benefit Source prices (unrounded): $16.8500; ministry $8.2600 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02321157 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80656
Interchangeable products
Drospirenone&Ethinyl Estradiol USP · DIN 02462060 · $8.2600 MYA · DIN 02415380 · $8.2600
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (68:32 Progestogens and Oral Contraceptives) and how they are covered

Matched class: 68:32 Progestogens and Oral Contraceptives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DESOGESTREL & ETHINYL ESTRADIOL, DROSPIRENONE, ETHINYL ESTRADIOL & NORETHINDRONE, ETHINYL ESTRADIOL & NORETHINDRONE ACETATE, LEVONORGESTREL Some products covered without a code (check the product listing): ETHINYL ESTRADIOL & LEVONORGESTREL, MEDROXYPROGESTERONE ACETATE, NORETHINDRONE, NORGESTIMATE & ETHINYL ESTRADIOL 68:32 Progestogens and Oral Contraceptives

DESOGESTREL & ETHINYL ESTRADIOL

· 12 products · General benefit · strengths: 0.15mg & 0.03mg, 3 Phase · Tab-21 Pk, Tab-28 Pk, Tabs-21 Pk, Tabs-28 Pk

ETHINYL ESTRADIOL & LEVONORGESTREL

· 20 products · General benefit (18), Off-Formulary Interchangeable, not an ODB benefit (2) · strengths: 20mcg & 100mcg, 0.03mg & 0.15mg, 3 Phase · Tab-21 Pk, Tab-28 Pk, Tab-91 Pk

ETHINYL ESTRADIOL & NORETHINDRONE

· 6 products · General benefit · strengths: 0.035mg & 0.5mg, 0.035mg & 1mg, 3 Phase · Tab-21 Pk, Tab-28 Pk

ETHINYL ESTRADIOL & NORETHINDRONE ACETATE

· 4 products · General benefit · strengths: 0.02mg & 1mg, 0.03mg & 1.5mg · Tab-21 Pk, Tab-28 Pk

DROSPIRENONE

· 1 products · General benefit · strengths: 4mg · Tab-28 Tab Pk

LEVONORGESTREL

· 4 products · General benefit · strengths: 1.5mg · Tab-1 Tab Pk

MEDROXYPROGESTERONE ACETATE

· 10 products · Temporary benefit (2), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (3), General benefit (4), Listed, not a benefit (1) · strengths: 150mg/mL, 2.5mg, 5mg, 10mg, 100mg · Inj Sol-1mL Pref Syr, Tab

NORETHINDRONE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 0.35mg · Tab-28 Pk

NORGESTIMATE & ETHINYL ESTRADIOL

· 10 products · Listed, not a benefit (4), General benefit (6) · strengths: 3 Phase · Tab-21 Pk, Tab-28 Pk

DIENOGEST

· 5 products · Limited Use, codes 432 · strengths: 2mg · Tab

CYPROTERONE ACETATE & ETHINYL ESTRADIOL

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2mg & 0.035mg · Tab-21 Pk

PROGESTERONE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:32
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: conception control
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: DESOGESTREL & ETHINYL ESTRADIOL DESOGESTREL & ETHINYL ESTRADIOL · General benefit • Conception control PM: https://pdf.hres.ca/dpd_pm/00077799.PDF; date NOV 20, 2024; DIN 02042479; fetched 2026-09-10 Product monograph ETHINYL ESTRADIOL & ETONOGESTREL · Off-Formulary Interchangeable, not an ODB benefit • Conception control PM: https://pdf.hres.ca/dpd_pm/00077755.PDF; date DEC 12, 2004; DIN 02253186; fetched 2026-09-10 Product monograph ETHINYL ESTRADIOL & LEVONORGESTREL · General benefit (18), Off-Formulary Interchangeable, not an ODB benefit (2) 1 Indications TRIQUILAR (levonorgestrel and ethinyl estradiol) is indicated for: • Conception control 1.1 Pediatrics Pediatrics (˂16 years of age): Based on the data submitted and reviewed by Health Canada, Health Canada has authorized an indication in women of reproductive age. PM: https://pdf.hres.ca/dpd_pm/00081001.PDF; date 2025-07-07; DIN 00707503; fetched 2026-09-10 Product monograph NORETHINDRONE · Listed, not a benefit (1), General benefit (2) INDICATIONS AND CLINICAL USE MOVISSE Tablets are indicated for conception control. PM: https://pdf.hres.ca/dpd_pm/00085300.PDF; date JUL 10, 2026; DIN 02410303; fetched 2026-09-10 Product monograph NORGESTIMATE & ETHINYL ESTRADIOL · Listed, not a benefit (4), General benefit (6) Indications TRI-CIRA LOTM 21 and TRI-CIRA LOTM 28 (Norgestimate and Ethinyl Estradiol Tablets) are indicated for:  Conception control. 1.1. PM: https://pdf.hres.ca/dpd_pm/00081457.PDF; date 2025-08-21; DIN 02401967; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 Indications YASMIN (drospirenone and ethinyl estradiol tablet) is indicated for: • Conception Control • Treatment of moderate acne vulgaris in women ≥16 years of age who have no known contraindications to oral contraceptive therapy, desire contraception, and have achieved menarche 1.1 Pediatrics Pediatrics (˂16 years of age): The safety and efficacy of YASMIN has not been established in women under the age of 16 years. Use of this product before menarche is not indicated (see 7.1.3 Pediatrics). 1.2 Geriatrics Geriatrics: YASMIN is not indicated for use in postmenopausal women. No data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use. https://pdf.hres.ca/dpd_pm/00080997.PDF PM date: 2025-07-07 Source product: YASMIN 21; DIN 02261723; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.